Background: Dexmedetomidine attenuates renal ischaemia and reperfusion (I/R) injury, but its mechanism of action is unclear. As sirtuin 3 (SIRT3) activation can alleviate acute kidney injury, we investigated whether dexmedetomidine acts through SIRT3 to reduce renal I/R injury. Methods: The potential involvement of SIRT3 in dexmedetomidine attenuation of renal I/R injury was tested in HK2 cells subjected to hypoxia/reoxygenation and C57BL/6J mice subjected to renal I/R. A short interfering RNA targeting SIRT3 was used in some experiments to examine the potential role of SIRT3. Cell death and mitochondrial membrane potential (Djm) were analysed in cultured cells. Mitochondrial damage in mice was assessed using electron microscopy and markers for renal function. Expression of cyclophilin D, cytochrome c, and SIRT3, and the level of cyclophilin D acetylation were determined. Results: Hypoxia/reoxygenation of HK2 cells increased cell death, cytochrome C expression, and cyclophilin D acetyla-
Ischaemia and reperfusion (I/R) can cause acute kidney injury, 1e4 and is characterised by increased production of reactive oxygen species (ROS) and mitochondrial damage, 5, 6 and disruption of cell polarity, cytoskeletal integrity, and cell-matrix and cell-cell interactions in renal tubular epithelial cells. 7 The mitochondrial protein sirtuin 3 (SIRT3) may help mitigate or prevent I/R injury. SIRT3 is one of several nicotinamide adenine dinucleotide (NAD þ )-dependent histone deacetylases that regulate a variety of functions in mammals, including ageing and metabolism.
8e10 SIRT3 activation protects mitochondria by deacetylating mitochondrial matrix proteins, including superoxide dismutase 2 and cyclophilin D. 11e13 SIRT3 overexpression or activation protects cardiomyocytes from injury by hydrogen peroxide 14 and attenuates myocardial I/R injury by deacetylating cyclophilin D and inhibiting the opening of the mitochondrial permeability transition pore (mPTP). 12 SIRT3 also stimulates mitochondrial activity to inhibit renal oxidative stress in animals receiving a high-fat diet. 13 SIRT3 overexpression helps restore mitochondrial dynamics in a model of acute kidney injury. 15 Whether and how SIRT3 is able to attenuate acute kidney injury induced by I/R remains unknown.
The a 2 -adrenoreceptors are widely distributed in the renal proximal and distal tubules, and peritubular tissues. 16 Dexmedetomidine activates a 2 -adrenoreceptors and thereby increases renal blood flow and glomerular filtration in animal studies, 16e18 and reduces perioperative acute kidney injury in clinical studies. 19, 20 In our previous work, we showed that dexmedetomidine inhibits apoptosis of tubular epithelial cells in an animal I/R model. 21 Other work has provided evidence regarding potential mechanisms of the protective effects of dexmedetomidine against mitochondrial injury. In neuro-2a cells, dexmedetomidine inhibited I/R-induced decreased mitochondrial membrane potential (Djm). 22 Dexmedetomidine reversed the collapse of Djm in A549 epithelial cells challenged with bilirubin, and attenuated bilirubin-induced lung injury in rats. 23, 24 These results raise the possibility of a connection between dexmedetomidine action and SIRT3, as this protein, as the major deacetylase in mitochondria, helps regulate injuryinduced opening of mPTP, limiting the exit of cytochrome c and apoptotic factors into the cytosol. 12,14,15 Therefore, we examined whether dexmedetomidine could alleviate renal I/R injury in a mouse model and the role of activation of SIRT3.
Methods

General design
In vitro experiments were conducted using the HK2 human renal proximal tubular epithelial line (ATCC, Manassas, VA, USA). Hypoxia and reoxygenation were conducted as previously described. 25 Cells were exposed to dexmedetomidine 0.1 nM (based on pilot experiments) or vehicle for 60 min before hypoxia. In some experiments, cultures were also treated with short interfering RNA (siRNA) targeting SIRT3 or negativecontrol siRNA at 24 h, or SIRT3 mimics at 48 h before dexmedetomidine treatment. Culture treatment conditions are provided in the Supplementary Material and summarised in
Supplementary Figure S1a and b. Cell death and Djm were measured using flow cytometry. Cells were harvested to determine the expression level of key proteins using western blotting and the level of acetylation of cyclophilin D using immunoprecipitation. Cultures were analysed in triplicate in three independent experiments (n¼3).
In vivo experiments were approved by the Institutional Animal Ethics Committee of Nanjing Medical University, and all procedures described here were performed in strict accordance with the institutional guidelines and reporting concurred with relevant aspects of the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines. Male C57BL/6J mice were obtained from the Animal Experiment Centre of Nanjing Medical University. Renal I/R were conducted as previously described. 21 At 30 min before ischaemia, mice were pretreated with dexmedetomidine (25 mg kg À1 i.p.) or vehicle. Some animals were also given anti-SIRT3 siRNA 3 days before I/R. Wild-type (WT) or SIRT3-knockdown mice were randomly allocated to undergo sham surgery (Sham) or I/R surgery either without pretreatment (I/R) or after dexmedetomidine pretreatment (DEXþI/R) (n¼ 8 per group). Further information on animal allocation and experimental manipulations is provided in the Supplementary Material and summarised in Supplementary Figure S1c and 
Cell death and Djm
Cell death was analysed in treated cultures using flow cytometry (FACS Calibur, BD Pharmingen, Heidelberg, Germany) at an excitation wavelength of 488 nm and an emission wavelength of 590 nm as described.
12
Djm was assessed using flow cytometry-based detection of 
SIRT3 knockdown in vivo
Mice were transfected with siRNA 5 0 -GCG TTG TGA AAC CCG ACA T-3 0 (GenePharma, Shanghai, China) targeting mouse SIRT3 (Gene ID: 64384) or scrambled control siRNA 5 0 -ACG TGA CAC GTT CGG AGA A-3 0 (Shanghai GenePharma). 30 siRNA (5 mg) was dissolved in RNase-free water (5 ml), mixed with Entranster TM in vivo transfection reagent (5 ml; Engreen Biosystem), and then injected via the tail vein 3 days before I/R. SIRT3 knockdown was verified with western blot analysis.
Renal function
Serum creatinine and plasma urea concentrations were determined using an automated biochemical analyser (AU2700, Olympus, Mishima, Japan). Serum concentrations of neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C were determined using standard enzyme immunoassay kits (Bioporto Diagnostics, Gentofte, Denmark).
Renal histology
Kidneys were post-fixed with 10% buffered formalin, dehydrated in graded ethanol solutions, embedded in paraffin, sectioned, and stained with haematoxylin and eosin. Acute tubular necrosis was graded using a scale of 0e4 based on involvement of the cortex or outer medulla: 0¼normal; 1¼minimal damage (<5% involvement); 2¼mild damage (5e25% involvement); 3¼moderate damage (25e75% involvement); 4¼severe damage (>75% involvement). 31 
Renal apoptosis
Apoptotic cells were detected using the TUNEL-based ApoTag peroxidase in situ apoptosis detection kit (Roche, Basal, Switzerland). Sections of 4 mm were deparaffinised, treated with proteinase K for 15 min at room temperature, incubated with a mixture of nucleotides and TdT enzyme for 1 h in a humidified atmosphere, then incubated with antidigoxygenin conjugated to horseradish peroxidase for 30 min. Nuclei were stained using 3,3-diaminobenzidine. For negative controls, TdT enzymes were omitted. Five randomly chosen fields were analysed at 400Â magnification.
Mitochondrial morphology of tubular epithelial cells in vivo
At 24 h after renal I/R, fresh renal tissue was harvested and renal cortical mitochondrial morphology of tubular epithelial cells was observed. The experimental manipulation is provided in the Supplementary Material.
Mitochondrial isolation and measurement of SIRT3 activity in vivo
Mitochondria were isolated as described. 32 Renal tissue was minced, rinsed twice in ice-cold MSM (D-mannitol 220 mM, sucrose 70 mM, 3-(N-morpholino)-propanesulfonic acid (MOPS) 5 mM, pH¼7.4) and homogenised in MSM buffer containing EDTA 2 mM and BSA 0.2%, then the homogenate was centrifuged for 20 min at 300 g at 4 C, and the supernatant was centrifuged at 7000 g three times (15 min each). The pellet was resuspended in MSM containing protease inhibitors, and stored at À80 C until assay. Samples were later thawed and SIRT3 activity was measured using a fluorescence assay (BPS Bioscience, San Diego, CA, USA) as described. 14 Protein concentration was determined using the Bicinchoninic Acid (BCA) Assay.
Immunoprecipitation and western blotting in vitro and in vivo 
Statistical analysis
Statistical analysis was carried out using SPSS 18.0 (IBM, Chicago, IL, USA). Data are shown as individual points when n¼3, and plotted as box and whisker plots showing median, interquartile range, and range when n¼8. Non-parametric data were evaluated using the KruskaleWallis tests with the post hoc Dunn's test. In all tests, P<0.05 was considered significant.
Results
Effects of dexmedetomidine on HK2 cultures exposed to hypoxia-reoxygenation Hypoxia-reoxygenation of HK2 cells increased cell death (Fig. 1A ) and reduced Djm (Fig. 1B) . Pretreatment with dexmedetomidine 0.01 or 0.1 nM attenuated such changes (Fig. 1A and  B) . Hypoxia-reoxygenation also decreased SIRT3 expression and increased cyclophilin D acetylation. Pretreatment with dexmedetomidine also attenuated the reduction in SIRT3 expression and cyclophilin D hyperacetylation. The expression of cyclophilin D was not affected by dexmedetomidine (Fig. 1CeE) .
Modulation of dexmedetomidine effects in HK2 cells by SIRT3 knockdown or overexpression
Dexmedetomidine ameliorated the changes in Djm, cell death, cytochrome c, and cyclophilin D acetylation induced by hypoxia-reoxygenation injury. Overexpression of SIRT3 enhanced the effects of dexmedetomidine pretreatment in HK2 cells exposed to hypoxia-reoxygenation injury (Fig. 2AeE) . siRNA-mediated SIRT3 knockdown reversed the protective effects of dexmedetomidine against injury induced by hypoxia-reoxygenation, but did not affect the changes induced by hypoxia-reoxygenation in the absence of dexmedetomidine (Fig. 3AeE) . 
Effects of dexmedetomidine on renal I/R injury in mice
I/R exposure increased the concentrations of serum creatinine, plasma urea, serum NGAL, and cystatin C (P<0.05 vs sham-operated animals; Fig. 4AeD ). Such effects were attenuated by dexmedetomidine pretreatment (P<0.05 vs I/R). Renal tubular cells in proximal tubules showed normal morphology and architecture in sham-operated controls (Fig. 4E, panel 1) . I/ R led to tubular dilatation and luminal congestion, cellular vacuolisation, tubular cell swelling, pyknotic nuclei, and severe tubular necrosis (Fig. 4E, panel 2) . Dexmedetomidine attenuated these morphological changes (Fig. 4E, panel 3 ; Fig. 4F ). I/R decreased expression of SIRT3, increased expression of cytochrome c, and increased cyclophilin D acetylation in renal tissue (P<0.05 vs sham); dexmedetomidine pretreatment attenuated these changes (P<0.05 vs I/R; Fig. 4GeJ ).
Modulation of dexmedetomidine effects in mice by SIRT3 knockdown
I/R exposure increased the concentrations of serum creatinine, plasma urea, NGAL, and cystatin C (P<0.05 vs sham; Fig. 5AeD ), and these changes were attenuated by dexmedetomidine pretreatment (P<0.05 vs I/R). Dexmedetomidine also reduced the number of apoptotic cells from 66 (43e72) to 27 (20e46) (P<0.05 vs I/R). SIRT3 knockdown abolished the effects of dexmedetomidine (P<0.05 vs DEXþI/R; Fig. 5AeD ), including the effect on apoptosis [67 (48e76) in siRNAþDEXþI/R vs 27 (20e46) in DEXþI/R, P<0.05; Fig. 5E and F.
Electron microscopy showed that I/R in mice significantly damaged tubular epithelial mitochondria (Fig. 5G) . At 24 h after the initiation of reperfusion, renal tubular epithelial cells with abnormal mitochondrial ultrastructure and epitheliocytes with altered mitochondrial ultrastructure were seen. In particular, a significant increase in the number of intercristae and the volume of the intermembrane space, and local brightening and swelling of mitochondrial matrix was apparent. The number of mitochondria cristae was reduced or even absent in some cases; cells with such mitochondria showed signs of degradation. Dexmedetomidine attenuated these ultrastructural changes, and this attenuation was abolished with SIRT3 knock-down.
I/R decreased SIRT3 activity by 51% (P<0.05 vs sham), while dexmedetomidine pretreatment increased it by 43% (P<0.05 vs I/R; Fig. 6B ). Similar changes were observed for SIRT3 expression ( Fig. 6A and C) . I/R increased cyclophilin D acetylation by 110% in kidney cells (P<0.05 vs sham), while dexmedetomidine decreased it by 33% (P<0.05 vs I/R; Fig. 6A and D) . Dexmedetomidine also inhibited cytochrome c expression (P<0.05 vs I/ R). All three effects of dexmedetomidine were abolished by SIRT3 knockdown (cf. WT and siRNA mice treated by DEXþI/R, Fig. 6 ).
Discussion
The present study explored whether mitochondrial SIRT3 was involved in the effects of the a 2 receptor agonist dexmedetomidine on I/R-induced renal injury in vitro and in vivo. Our data with hypoxia-damaged HK2 cells clearly demonstrate a functional role of SIRT3 in preventing cyclophilin D acetylation and loss of Djm, subsequently preserving mitochondrial integrity and cell survival. These findings were corroborated in a mouse model of acute kidney injury, in which the expression and activity of mitochondrial SIRT3 decreased at the same time that cyclophilin D was hyperacetylated and Djm collapsed, resulting in cell apoptosis and renal dysfunction. Dexmedetomidine pretreatment increased SIRT3 expression in vitro and in vivo, inhibiting cyclophilin D acetylation and alleviating mitochondrial damage and cellular apoptosis, ultimately improving renal function. Dexmedetomidine did not exert protective effects against renal I/R injury in vitro or in vivo when SIRT3 was knocked down. These results suggest that dexmedetomidine protects against renal I/R injury by preserving mitochondrial SIRT3 activity. I/R triggers acute kidney injury by causing damage to the renal tubules, where cells are rich in mitochondria. Alterations in mitochondria are a hallmark in disease initiation and progression, 3, 32 and surgery and anaesthesia can disturb the balance between production of ROS and antioxidant defences, making mitochondria particularly susceptible to damage 32 and leading to initiation of apoptosis. 33 In this process, opening of the mPTP initiates Djm collapse, leads to the release of the apoptotic factors cytochrome c, BAX, and BCL-2, and disrupts ATP production, triggering the caspase cascade and initiating apoptosis. 34e36 The mitochondrial matrix protein cyclophilin D triggers mPTP opening, leading to the creation of a tunnel-like structure that connects the matrix with the cytosol, 12,37 thereby facilitating renal I/R injury. 34 Cyclophilin D hyperacetylation has been implicated in renal oxidative stress, 13 neuronal damage and neurodegeneration, 38 severe haemorrhagic shock, 39 age-related cardiac hypertrophy, 37 and myocardial I/R injury. 12 The present study extends this list by implicating increased acetylation of cyclophilin D in renal I/R injury in vitro and in vivo. The increase in acetylation alters the probability of mPTP opening, which we observed as loss of Djm. These effects were reversed by dexmedetomidine, which also alleviated histological signs of I/R injury. This is reminiscent of the way in which the cyclophilin D inhibitor cyclosporine A reverses the mitochondrial abnormality associated with cyclophilin D hyperacetylation. 37 These results indicate that cyclophilin D acetylation and the associated mitochondrial dysfunction play a critical role in renal I/R injury. Our results also extend the list of tissues in which mitochondria appear to mediate the protective effects of dexmedetomidine, which has already been shown in neurones and lungs. As SIRT3 is a deacetylase, we questioned whether it might be involved in cyclophilin D-dependent modulation of mPTP opening during renal I/R. Our results are consistent with the idea that the deacetylase SIRT3 helps regulate mPTP opening in the context of myocardial reperfusion injury 40 and renal oxidative stress. 41 For example, SIRT3 appears to deacetylate cyclophilin D and thereby block it from binding to adenine nucleotide translocator, 42 preventing mPTP opening and protecting cells from myocardial infarction. 12 This may help explain the ability of SIRT3 to alleviate the mitochondrial dysfunction and cell apoptosis that occur, for example, in acute kidney injury. 10,43e45 Consistent with this literature, our in vitro experiments suggest that SIRT3 overexpression on the background of hypoxia-reoxygenation prevents cyclophilin D hyperacetylation, preserving Djm, and ultimately attenuating cell death, whereas SIRT3 knockdown tends to depolarise mitochondria and trigger cell death. We corroborated our in vitro findings using an in vivo model of renal I/R injury, which reduced SIRT3 expression and activity, increased cyclophilin D acetylation, and triggered Djm collapse and cell apoptosis.
These changes were linked to renal tubular function disorder, based on elevated serum NGAL and cystatin C concentrations; and they were linked to renal dysfunction, based on increased serum creatinine and plasma urea. Our results suggest that hypoxia-reoxygenation and I/R stress the integrity of the mPTP and the ability of SIRT3 to prevent tissue injury. Several studies have shown that dexmedetomidine protects against renal I/R injury, but how it does so remains unclear. Our present findings regarding the effects of dexmedetomidine on renal cell injury in vitro and in vivo are consistent with our previous work showing that dexmedetomidine inhibits tubular epithelial apoptosis and subsequently attenuates renal injury in animals, 21 as well as with studies from other groups showing that dexmedetomidine relieves mitochondrial swelling and vacuolisation in the dorsal root ganglion induced by neuropathic pain 22 ; attenuates oxidative stress-induced lung alveolar epithelial cell apoptosis by preventing ROS generation, cytochrome c release, and resulting cell cycle arrest 24 ; and reverses up-regulation of cytochrome c and Djm collapse in A549 epithelial cells under bilirubin challenge. 23 Studies have also demonstrated the benefits of dexmedetomidine against renal injury in patients undergoing major operations such as cardiovascular surgery. 17, 46 In fact, dexmedetomidine is widely used in the clinic because of its sedative, analgesic, sympatholytic, and haemodynamic effects on patients during the perioperative period; it also has antioxidant, anti-inflammatory, and anti-apoptosis effects on vital organs, such as the heart, brain, lung, and kidney. 16, 19, 22, 24 However, one study has suggested that dexmedetomidine induces the caspase cascade and loss of Djm, leading to apoptosis of human neutrophils in healthy volunteers. 25 While this raises the possibility that the drug functions differently in healthy or diseased mitochondria, numerous studies, and our results, concur that dexmedetomidine can inhibit mitochondrial disruption and resulting renal dysfunction, possibly by preventing Djm collapse and cytochrome c release.
Our in vivo experiments provide clear evidence that dexmedetomidine influences cyclophilin D acetylation by influencing SIRT3 activity. We found an inverse correlation between SIRT3 expression levels (WT, overexpressed, or knocked down) and cyclophilin D acetylation. Our observation that dexmedetomidine limited mitochondrial damage and subsequent renal dysfunction in WT mice but not in SIRT3-knockdown animals is strong evidence in support of the idea that dexmedetomidine helps alleviate acute kidney injury by restoring and maintaining mitochondrial homeostasis and inhibiting cell apoptosis by stimulating SIRT3 activity and causing cyclophilin D deacetylation.
Taken together, our findings suggest new perspectives toward protective and therapeutic targets to prevent perioperative renal I/R injury. Future studies should examine whether modification of the NAD þ /NADH ratio known to occur during prolonged I/R 40 affects SIRT3 activity: lowering of the NAD þ / NADH ratio may result in insufficient SIRT3 activation, leading to hyperacetylation of cyclophilin D and facilitating mPTP opening. 42, 43 Future studies should also examine whether the ability of dexmedetomidine to inhibit Djm collapse in the context of I/R injury involves its ability to reduce depolarisation-induced increases in intra-synaptosomal Ca 2þ concentrations. 47 In summary, our cell culture and in vivo data suggest that deficiency of the mitochondrial enzyme SIRT3 after prolonged renal I/R facilitates cyclophilin D acetylation, mPTP opening, and subsequent cell death. Dexmedetomidine appears to protect against I/R injury by up-regulating SIRT3. These insights may help guide efforts to prevent renal I/R injury perioperatively.
